Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
1 drug for “Advanced or Metastatic NRAS-mutant Melanoma”
Phase 3 1
- NaporafenibErasca, Inc.Advanced or Metastatic NRAS-mutant Melanoma
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.